Mosa Meat announced on 22 January 2025 that it had submitted its cultivated beef fat to the European Commission for novel food authorisation. EFSA’s application register records the dossier as received on 13 February 2026 — 387 days later. As of 30 June 2026 it had still not been validated, which means the nine-month scientific assessment EFSA is required to complete had not begun.

Nothing had gone wrong. That is the point. No public record shows the dossier rejected, withdrawn or returned. It was in the part of the process nobody schedules around, because almost nobody publishes what happens there.

This piece assembles what the first half of 2026 actually looked like in the EU novel food queue: what was authorised, what was validated, what was merely received, and how long each stage is taking. It is a direct follow-up to our analysis of the EU precision fermentation approval gap, and one claim in that piece now needs correcting.

Methodology and its limits

The application-level data here comes from two statistical reviews published by CIRS Group, a regulatory consultancy, covering Q1 2026 and H1 2026. CIRS states its source is Open EFSA, the Authority’s public application register, and appends its own caveat: “There may be omissions and errors in the data statistics process.”

We were not able to query Open EFSA directly and reproduce the extraction. Every application-level date below is therefore CIRS’s reading of that register rather than ours. Where CIRS’s two reports disagree with each other, we say so.

The timeline statistics come from a separate, peer-reviewed source: a 2025 npj Science of Food Perspective by Le Bloch and colleagues at FoodChain ID, which analysed 292 novel food applications submitted under Regulation (EU) 2015/2283 between 2018 and 2024, with data collection completed on 4 October 2024. Those are population averages from a closed dataset, not a live measurement of 2026 conditions.

What moved in the first half of 2026

Stage Q1 2026 H1 2026
Novel foods authorised by the Commission 3 6
Dossiers received by EFSA 7 19
Dossiers validated by EFSA 9 15
Scientific opinions published 2 9

Six authorisations in six months, of which four were new novel foods and two were changes to the specifications or use conditions of products already on the Union list. The six: defatted rapeseed powder (NapiFeryn BioTech), pasteurised Akkermansia muciniphila (the Akkermansia Company), lacto-N-tetraose (Inbiose), inulin-propionate ester (Imperial College Hammersmith Campus), rhamnogalacturonan-I enriched carrot extract (NutriLeads) and Jatropha curcas kernels (Chuta Nut).

Not one is an alternative protein.

Practical consequence: a company modelling EU entry off the headline authorisation rate is modelling the wrong pipeline. The six products authorised in H1 2026 are botanicals, a postbiotic, an HMO and two fibre-adjacent ingredients. Recombinant food proteins and cell-cultivated biomass are not in the authorisation column at all. They are further back, and the distance is measured in years.

The validation phase is the clock nobody prices

Regulation (EU) 2015/2283 gives EFSA nine months to deliver an opinion once it receives a valid application from the Commission. Everything before the word valid is unbudgeted time.

The npj analysis breaks that pre-assessment period into two measured stages across 194 applications:

Stage Mean Standard deviation Observed range
Commission verifies the application (A) 114 days ±181 0–1,430 days
EFSA suitability and completeness check (B) 185 days ±122 15–758 days
Whole validation phase (A+B) 299 days ±218 20–1,635 days
EFSA scientific evaluation once validated (C) 629 days ±338 179–1,714 days
Opinion adoption to publication (D) 48 days ±16 26–107 days
Submission to published opinion (total) 937 days ±436 330–2,314 days

Read the first row against its standard deviation. A mean of 114 days with a spread of ±181 and a maximum of 1,430 is not a process with a typical duration. It is a queue. Mosa Meat’s 387 days sits well outside the mean and comfortably inside the observed range.

The evaluation stage tells the same story from the other side. EFSA’s statutory window is nine months — roughly 274 days — and the measured mean is 629. But the overrun is mostly not EFSA sitting on dossiers. Applications receive an average of 2.7 requests for additional data, applicants take an average of 130 days to answer each one, and the time applicants spend responding accounts for 47% ± 25% of the total evaluation period. On the authors’ own accounting, EFSA’s share is 53%.

Only 24 of 93 completed applications — 26% — formally exceeded the nine-month period, with a mean overrun of 156 days. Three quarters stayed inside the statutory clock. The clock simply is not where the time goes.

Practical consequence: the budget line that matters is not regulatory affairs headcount for the assessment year. It is the capacity to answer roughly three unscheduled scientific data requests, each potentially requiring new studies, spread across an unknown two-to-three-year window. A company that treats EU submission as a filing cost rather than a multi-year research commitment has mispriced it.

What EFSA validated, and the one that matters

Fifteen dossiers cleared validation in H1 2026 and entered scientific assessment. The list repays close reading, because “fermentation-derived” covers several different things that are not commercially interchangeable.

Substance Applicant Validated What it is
Chuta® (modification) Chuta Nut GmbH 6 Jan 2026 Plant kernel
2’-Fucosyllactose via Kluyveromyces lactis Hengrui (Qingdao) Biotechnology 12 Jan 2026 HMO — a carbohydrate
6’-Sialyllactose sodium salt (modification) Cataya Bio (Shanghai) 12 Jan 2026 HMO — a carbohydrate
Calcifediol Carbogen Amcis BV 14 Jan 2026 Vitamin D metabolite
β-Nicotinamide Mononucleotide Borealis Pharma Manufacturing 19 Feb 2026 Small molecule
Schizochytrium sp. (LU310) oil LinYi YouKang Biology 27 Feb 2026 Algal oil
Quercetine from Dimorphandra mollis SC2S 16 Mar 2026 Plant extract
Xylose isomerase Intoleran 16 Mar 2026 Enzyme
Human-equivalent lactoferrin alpha Helaina Inc. 25 Mar 2026 Recombinant food protein
Coffee fruit extract VDF FutureCeuticals 7 Apr 2026 Plant extract
2’-Fucosyllactose via E. coli BL21 珠海市朗健生物科技有限公司 23 Apr 2026 HMO — a carbohydrate
Cannabidiol – natural Cibdol AG 29 Apr 2026 Plant extract
Xia Powder 435 (modification) BENEXIA 5 May 2026 Seed powder
Gamma-aminobutyric acid Bloomage Biotechnology 8 May 2026 Amino acid
Defatted passion fruit seed extract ALIDANS Srl 8 May 2026 Plant extract

Several of these are made by fermentation, and two are proteins in the strict sense — xylose isomerase is an enzyme. Exactly one is a protein sold as a food ingredient and produced by precision fermentation: Helaina’s human-equivalent lactoferrin alpha, validated on 25 March 2026.

That single row is the update our August analysis needs. That piece recorded that Perfect Day’s dossier died in validation after two years and Remilk withdrew, and that neither had ever reached scientific assessment. As of 25 March 2026, one recombinant food protein has. The claim that no precision-fermented protein had entered EFSA’s scientific evaluation was accurate when written and is now out of date.

It is a narrow update, not a reversal. Validation is not authorisation. On the npj figures, the mean remaining path is another 629 days to an adopted opinion, then a Commission implementing act and a Member State vote. The EU has still authorised zero precision-fermented proteins.

Why this one, and not a whey or an egg protein

The most useful thing about Helaina’s dossier is which protein it is.

Bovine lactoferrin has been approved as a food ingredient in Europe since 2012. EFSA’s mandate under Regulation (EU) 2015/2283 is to assess a novel food’s hazards and risks “notably compared to similar food already on the EU market,” in the npj authors’ summary of Articles 7 and 11.2. A recombinant human-equivalent lactoferrin arrives with an authorised animal-derived comparator already sitting on the Union list, a large published safety literature, and a defined use category.

Precision-fermented β-lactoglobulin and ovalbumin — the proteins behind the two dossiers that failed — have comparators too, but arrived as the first of their kind through a framework that had not yet published its microorganism guidance. We are not asserting causation here; we have not seen EFSA’s reasoning on any of these files, and the earlier failures are documented as procedural, tied to the Transparency Regulation’s study-notification rules, rather than scientific.

Practical consequence, stated as a hypothesis worth testing rather than a finding: if the presence of an authorised comparator materially eases validation, the rational EU sequencing for a precision-fermentation portfolio is to file the molecule with the closest authorised analogue first, and use the resulting file as precedent — not the molecule with the largest addressable market. That is close to the opposite of how most launch plans are built. We set out the general version of this problem in our launch-market comparison.

Who is actually filing

The other structural feature of the H1 2026 queue is who is in it. CIRS counts six Chinese applications submitted or validated in the half, five of which had already reached formal validation, concentrated in HMOs and fermentation-derived ingredients. Across the full received list, CIRS’s summary is that plants and plant-derived extracts together with microbial fermentation-derived ingredients “remained the dominant categories,” with overseas botanicals continuing to attract significant interest.

Alternative protein is a small minority of a queue composed mostly of supplement, infant nutrition and botanical ingredients — different data packages, different precedents, different commercial urgency. Anyone reading EFSA throughput as a signal about their own category should note that it largely is not one.

What Mosa Meat actually filed

The scale of the dossier matters, because it bears on whether a long completeness check is unreasonable. By the company’s own account the submission ran to almost 1,000 pages, drew on 450 samples and 652 analytical documents, involved six accredited laboratories, required 23 new analytical methods and 148 parameters per batch, occupied more than ten full-time employees for nearly two years, and took seven consecutive days simply to upload to the Commission’s portal. FoodNavigator’s contemporaneous report corroborates the page count, the sample count and the two-year, ten-person effort.

Mosa Meat also explained why it filed fat rather than a finished product: EFSA assesses each novel ingredient individually, unlike Singapore, where entire products are assessed. Chief executive Maarten Bosch framed the choice commercially — “Fat is the soul of flavor” — but the regulatory logic is that a single ingredient is the smallest unit that can be pushed through this system.

At submission, FoodNavigator reported the expectation that EFSA’s risk assessment would take around 18 months. Eighteen months after the announcement, the assessment had not started.

The counter-argument

The strongest case against reading this as regulatory failure has three parts, and it is better than it first appears.

First, outcomes are good. On the npj data, 86.81% of published EFSA opinions are positive. This is a slow system, not a hostile one. It is also a discriminating one: of the nine opinions published in H1 2026, four concluded that safety could not be established.

Second, EFSA has improved specifically where this sector needs it. Le Bloch, generally critical of the Authority, singles out its 2024 guidance on microorganism-derived novel foods. “The recent guidance on microorganisms is really well done and provides all requirements depending on the characteristics of the ingredient,” he told NutraIngredients. “This guidance is pragmatic, so clearly, for precision fermentation, EFSA has done a great job.”

Third, cultivated bovine fat is genuinely unprecedented in this framework. There is no completed EU assessment of any cell-cultivated product to reason from. A long completeness check on the first dossier of its kind is not the same failure as a long check on the fortieth botanical extract.

Against that, Le Bloch’s central complaint stands: there is still no route to substantive scientific dialogue before submission. “There is still no possibility to exchange with EFSA on the scientific content of the application,” he said. He cites a case in which the same data package cleared the United States in under six months and remained under EU evaluation five years later. Companies generate studies reactively, after questions are asked, which is the mechanism that turns 2.7 data requests into 353 days of cumulative response time.

What we could not establish

  • Mosa Meat’s exact submission date. We used 22 January 2025, the date of the company’s announcement and of FoodNavigator’s report. The filing may have preceded the announcement, in which case 387 days is a floor rather than a ceiling. The Commission does not publish submission dates.
  • Current status of the Mosa Meat dossier. Our data ends at 30 June 2026, the cut-off of the CIRS H1 report. We cannot say whether it was validated in July or early August 2026.
  • Helaina’s US regulatory status. Helaina does not appear among the twelve FDA clearances we counted in our GRAS database, and we found no GRAS notice number or FDA response letter for effera in any source we fetched. We are not treating that absence as proof that no notice exists. FoodNavigator’s July 2026 survey of the category names FDA “no questions” letters for TurtleTree (2025) and All G (April 2026) and self-affirmed GRAS for Vivici (February 2026), but states no US status for Helaina.
  • Gourmey’s EU status. Gourmey filed the first EU cultivated meat application, in 2024. It appears in neither the H1 2026 received nor validated tables, and we could not confirm whether it has been validated, is still in the completeness check, or has been rejected.
  • A source conflict on one date. CIRS’s Q1 report gives 10 January 2026 as the receipt date for the Handok Healthcare turmeric oleoresin dossier; its H1 report gives 10 February 2026 for the same item. That date is used in no calculation here. It is flagged because it bears on how tightly the rest of the extraction should be read.
  • The applicant name for one dossier. CIRS lists the applicant for 2’-fucosyllactose via E. coli BL21 only in Chinese. We have reproduced it as given rather than publishing an unverified transliteration.
  • Whether the 2024 guidance has changed timelines. It applies from 1 February 2025. The npj dataset closes in October 2024, so no published analysis yet measures its effect.

What to watch

Three testable claims, so this piece can be checked later rather than quietly forgotten:

  1. Mosa Meat’s dossier will appear in a CIRS or Open EFSA validation list before the end of 2026. If it does not, the pre-assessment wait on the first cell-cultivated beef dossier in the EU will have passed two years from announcement.
  2. Helaina’s lactoferrin will receive at least one request for additional data before any opinion is adopted. The base rate is 2.7 requests per application. Zero would be unusual enough to be worth explaining.
  3. No precision-fermented protein will be added to the Union list during 2026. On the published timelines there is no candidate close enough for this to be a near thing. We expect to restate it unchanged in January.

A fourth thing to track rather than predict: Vivici has said it has initiated the EU approval process for its precision-fermented lactoferrin. If a second lactoferrin dossier clears validation faster than the first, the comparator hypothesis above gets its test.

If any of the three claims turns out wrong, the correction belongs in an update to this article rather than a fresh one.